CIPLA's weekly performance was disappointing, with a return of -2.16% and a max drawdown of -2.55%, indicating a decline in stock value. The stock's volatility was moderate at 13.53%, which is higher than SUNPHARMA but lower than GRASIM. Compared to its peers, CIPLA underperformed SUNPHARMA and significantly lagged behind DIVISLAB. The stock's Sharpe Ratio of -0.64 suggests that it was a relatively risky investment this week.

[Volatility: 13.53%]